Developer docs
API playgroundTry for free, no card

Search company profiles

Everads Therapy

Full company profile

uuid000evuo

Namestring
Everads Therapy
Legal namestring
Everads Therapy
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Everads Therapy is an Israeli medical device and drug delivery company founded in 2017 within the RAD Biomed Accelerator in Tel Aviv, developing a proprietary suprachoroidal space (SCS) delivery platform for retinal disease therapeutics. The core technology is a geometrically-optimized, non-sharp tissue separator that enables tangential injection into the suprachoroidal space, providing rapid and extensive distribution of therapies to the posterior segment and macula. The device is compatible with standard Luer lock syringes and is engineered to deliver high volumes and large particles, making it suitable for gene therapies, cell therapies, suspensions, and slow-release formulations. The underlying technology was licensed from Sheba Medical Center at Tel Hashomer, and the platform has been validated in more than 60 non-human primates across multiple modalities including AAV vectors, anti-VEGF antibodies, and nanoparticles. A first-in-human clinical trial in diabetic macular edema using triamcinolone acetonide suspension has been completed, with results published in Ophthalmology Science in 2026.

Short descriptiontext

Everads Therapy is an Israeli medical device company developing a proprietary suprachoroidal drug delivery platform for retinal disease therapies, licensing its injector technology to pharmaceutical and biotech partners including Kriya Therapeutics and VivaVision for gene therapy and small-molecule ocular applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
suprachoroidal drug delivery, retinal disease therapy, ophthalmic injection devices, ocular drug delivery, posterior segment delivery
Industry3 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Patent Owners & Lessors6794
Product category
Ophthalmic Drug Delivery Devices
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Technology licensing
TypeLicensing Royalties
Description

Everads licenses its suprachoroidal delivery technology to pharmaceutical and biotech companies for specific retinal targets. Partners pay pre-agreed license fees, development milestones, and royalties in exchange for exclusive or non-exclusive rights to use the technology for defined ocular targets.

everads-therapy.com
2Collaborative development partnerships
TypeLicensing Royalties
Description

Co-development arrangements with partners where Everads provides its delivery technology while partners contribute development funding, with potential milestone payments and future royalty streams upon successful commercialization.

everads-therapy.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Everads Therapy develops and licenses a proprietary suprachoroidal (SCS) drug and cell delivery platform — the Everads Suprachoroidal Injector — that uses a geometrically-optimized non-sharp tissue separator to enable tangential injection into the suprachoroidal space for targeted delivery of gene therapies, cell therapies, anti-VEGF antibodies, suspensions, and slow-release formulations to the posterior segment and macula for retinal disease treatment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Procedural feasibility demonstrated in office-based setting with thermal imaging confirming rapid, posteriorly directed drug distribution to posterior pole and macular region
+1 more record
Product overview1 text field

Everads Therapy is an emerging startup developing a novel suprachoroidal delivery platform technology for retinal diseases. The core product is the Everads Suprachoroidal Injector (also referred to as the Everads Drug Delivery System), which enables targeted injection of therapies into the suprachoroidal space (SCS). The platform has been validated in over 60 non-human primates using various modalities including AAV vectors, anti-VEGF antibodies, nanoparticles, and other materials. The company is developing an early-stage pipeline leveraging this technology and has entered licensing and collaboration agreements with pharmaceutical partners including Kriya Therapeutics and VivaVision. The technology was founded in 2017 within the RAD Biomed Accelerator in Tel Aviv, with underlying technologies licensed from Sheba Medical Center.

Product and service2 records
1Everads Suprachoroidal Injector
CategoryOphthalmic Medical Device
Description

A novel suprachoroidal delivery device that enables targeted, rapid injection of therapies into the suprachoroidal space (SCS) for treatment of retinal diseases. The device features a proprietary geometrically-optimized non-sharp tissue separator that opens a path into the SCS, enabling tangential injection for rapid and extensive drug distribution to the posterior segment and macula. It is licensed to pharmaceutical and biotech partners.

2Everads Drug Delivery System
CategoryOphthalmic Drug Delivery Platform
Description

A suprachoroidal space (SCS) delivery platform technology that facilitates targeted, rapid delivery of therapies to the choroid and retina. The system enables delivery of high volumes and large particles, supporting gene therapy, cell therapy, suspensions, and slow-release formulations for retinal disease treatment.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-01
Description

Exclusive license and collaboration agreement for development of ocular gene therapy candidates using Everads' suprachoroidal delivery technology. Kriya is developing gene therapies for prevalent ophthalmology diseases including geographic atrophy. Everads' technology enables improved distribution of gene therapies to the posterior segment and macula.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Collaboration to develop durable and effective therapies for retinal diseases. Delivery of VivaVision's best-in-class molecules via the suprachoroidal space using Everads' technology is expected to lead to novel treatments for retinal diseases.

Strategic tierMinorTypeOthersAnnounced on2022-07-01
Description

Israel's Innovation Authority awarded a competitive grant to fund Everads' research and development. CEO Moshe Weinstein stated that the grant represents validation of the strong business and scientific case for Everads' technology and pipeline.

4Clinical-Stage Gene Therapy Company (unnamed)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

Collaboration to evaluate Everads' suprachoroidal delivery technology with a clinical-stage gene therapy company. Under the collaboration, the partner was given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties.

everads-therapy.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-03-01
Description

Option agreement with global pharma company to license Everads' suprachoroidal delivery system for retinal disease therapies. The agreement supports the potential of Everads' novel technology for delivery of posterior segment therapeutics to the suprachoroidal space. In August 2020, the company exercised rights for exclusive use of Everads' technology in specific retinal targets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Kriya is an Everads partner developing gene therapies for prevalent ophthalmology diseases including geographic atrophy. While not a direct delivery device competitor, Kriya operates in the same ocular gene therapy value chain and represents both a customer and a strategic reference point for SCS-enabled therapeutics.

TypeEmerging player
Description

Adverum develops AAV-based gene therapies for retinal diseases including wet AMD and diabetic macular edema, utilizing intravitreal delivery. Both Everads and Adverum compete in the broader ocular gene therapy delivery ecosystem with overlapping indication focus.

3Santen Pharmaceutical
TypeBroad incumbent
Description

Santen is a global ophthalmology-focused pharmaceutical company with products for retinal diseases, glaucoma, and dry eye. As a large incumbent in ophthalmic therapeutics, Santen represents a potential licensing partner and competitor in the broader retinal disease treatment landscape.

TypeDirect peer
Description

Clearside is the most direct competitor in suprachoroidal space delivery, with its commercially approved XIPERE SCS Microinjector for macular edema and active partnerships with large pharma. Both companies target the SCS delivery route for posterior segment therapeutics with injection-based devices.

TypeEmerging player
Description

4DMT develops customized AAV vectors for retinal and other diseases with an active ocular gene therapy pipeline. Both companies serve the emerging gene therapy delivery market, with overlapping customer base of pharma partners developing retinal disease therapeutics.

TypeDirect peer
Description

REGENXBIO develops AAV gene therapies for retinal diseases (RGX-314) using suprachoroidal delivery, partnering with AbbVie. Both companies are pursuing SCS delivery as the enabling route for ocular gene therapy, addressing overlapping indications such as wet AMD and diabetic retinopathy.

TypeBroad incumbent
Description

Ocular Therapeutix develops sustained-release ocular drug delivery platforms including DEXTENZA for post-surgical ocular inflammation and pain. Both companies develop drug delivery technologies for ocular indications, though Ocular Therapeutix focuses on anterior segment while Everads targets posterior segment.

TypeDirect peer
Description

EyePoint develops sustained-release ocular drug delivery technologies including DURYSTA and bioerodible implants for retinal diseases. Both Everads and EyePoint are ocular drug delivery platform companies targeting improved efficacy and durability of retinal disease treatments.

TypeEmerging player
Description

Kodiak develops novel biologics and conjugates (ABC platform) for retinal vascular diseases including wet AMD and DME. Both companies pursue improved durability of treatment for retinal diseases through differentiated therapeutic and delivery approaches.

TypeBroad incumbent
Description

Bausch + Lomb is a major ophthalmic pharmaceutical and device company with products across retinal diseases (e.g., Visudyne, enVista). Its broad portfolio in retinal therapeutics makes it a potential strategic acquirer or licensing partner for suprachoroidal delivery technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Everads Therapy

Ophthalmic Drug Delivery Deviceseverads-therapy.com

Everads Therapy is an Israeli medical device company developing a proprietary suprachoroidal drug delivery platform for retinal disease therapies, licensing its injector technology to pharmaceutical and biotech partners including Kriya Therapeutics and VivaVision for gene therapy and small-molecule ocular applications.

What Everads Therapy does

Everads Therapy is an Israeli medical device and drug delivery company founded in 2017 within the RAD Biomed Accelerator in Tel Aviv, developing a proprietary suprachoroidal space (SCS) delivery platform for retinal disease therapeutics. The core technology is a geometrically-optimized, non-sharp tissue separator that enables tangential injection into the suprachoroidal space, providing rapid and extensive distribution of therapies to the posterior segment and macula. The device is compatible with standard Luer lock syringes and is engineered to deliver high volumes and large particles, making it suitable for gene therapies, cell therapies, suspensions, and slow-release formulations. The underlying technology was licensed from Sheba Medical Center at Tel Hashomer, and the platform has been validated in more than 60 non-human primates across multiple modalities including AAV vectors, anti-VEGF antibodies, and nanoparticles. A first-in-human clinical trial in diabetic macular edema using triamcinolone acetonide suspension has been completed, with results published in Ophthalmology Science in 2026.

Everads Therapy firmographics

Firmographics
Name
Everads Therapy
Legal name
Everads Therapy
Website
https://everads-therapy.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Everads Therapy is an Israeli medical device company developing a proprietary suprachoroidal drug delivery platform for retinal disease therapies, licensing its injector technology to pharmaceutical and biotech partners including Kriya Therapeutics and VivaVision for gene therapy and small-molecule ocular applications.
Ownership category
akta.pro rank

Everads Therapy industry classification

Industry
Product category
Ophthalmic Drug Delivery Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841), Patent Owners & Lessors (6794)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Suprachoroidal drug delivery
  • Retinal disease therapy
  • Ophthalmic injection devices
  • Ocular drug delivery
  • Posterior segment delivery

Where Everads Therapy is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Everads Therapy business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Technology licensing: Everads licenses its suprachoroidal delivery technology to pharmaceutical and biotech companies for specific retinal targets. Partners pay pre-agreed license fees, development milestones, and royalties in exchange for exclusive or non-exclusive rights to use the technology for defined ocular targets.
  2. Collaborative development partnerships: Co-development arrangements with partners where Everads provides its delivery technology while partners contribute development funding, with potential milestone payments and future royalty streams upon successful commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Everads Therapy product offering

Product offering

Core offering

Everads Therapy develops and licenses a proprietary suprachoroidal (SCS) drug and cell delivery platform — the Everads Suprachoroidal Injector — that uses a geometrically-optimized non-sharp tissue separator to enable tangential injection into the suprachoroidal space for targeted delivery of gene therapies, cell therapies, anti-VEGF antibodies, suspensions, and slow-release formulations to the posterior segment and macula for retinal disease treatment.

Product overview

Everads Therapy is an emerging startup developing a novel suprachoroidal delivery platform technology for retinal diseases. The core product is the Everads Suprachoroidal Injector (also referred to as the Everads Drug Delivery System), which enables targeted injection of therapies into the suprachoroidal space (SCS). The platform has been validated in over 60 non-human primates using various modalities including AAV vectors, anti-VEGF antibodies, nanoparticles, and other materials. The company is developing an early-stage pipeline leveraging this technology and has entered licensing and collaboration agreements with pharmaceutical partners including Kriya Therapeutics and VivaVision. The technology was founded in 2017 within the RAD Biomed Accelerator in Tel Aviv, with underlying technologies licensed from Sheba Medical Center.

Differentiator

Problem solved

Functional benefit

Products and services

  • Everads Suprachoroidal Injector A novel suprachoroidal delivery device that enables targeted, rapid injection of therapies into the suprachoroidal space (SCS) for treatment of retinal diseases. The device features a proprietary geometrically-optimized non-sharp tissue separator that opens a path into the SCS, enabling tangential injection for rapid and extensive drug distribution to the posterior segment and macula. It is licensed to pharmaceutical and biotech partners.
  • Everads Drug Delivery System A suprachoroidal space (SCS) delivery platform technology that facilitates targeted, rapid delivery of therapies to the choroid and retina. The system enables delivery of high volumes and large particles, supporting gene therapy, cell therapy, suspensions, and slow-release formulations for retinal disease treatment.

Quantifiable outcome

  • Procedural feasibility demonstrated in office-based setting with thermal imaging confirming rapid, posteriorly directed drug distribution to posterior pole and macular region
  • +1 more outcomes

Companies that use Everads Therapy

Customer profile

Segments1 record

Ideal customer profiles1 record

Everads Therapy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Everads Therapy partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Kriya TherapeuticscoreTechnology or Integration · 1 September 2023Exclusive license and collaboration agreement for development of ocular gene therapy candidates using Everads' suprachoroidal delivery technology. Kriya is developing gene therapies for prevalent ophthalmology diseases including geographic atrophy. Everads' technology enables improved distribution of gene therapies to the posterior segment and macula.
  • VivaVisioncoreStrategic or Co-development Partner · 1 January 2023Collaboration to develop durable and effective therapies for retinal diseases. Delivery of VivaVision's best-in-class molecules via the suprachoroidal space using Everads' technology is expected to lead to novel treatments for retinal diseases.
  • Israel Innovation AuthorityminorOthers · 1 July 2022Israel's Innovation Authority awarded a competitive grant to fund Everads' research and development. CEO Moshe Weinstein stated that the grant represents validation of the strong business and scientific case for Everads' technology and pipeline.
  • Clinical-Stage Gene Therapy Company (unnamed)coreStrategic or Co-development Partner · 1 June 2021Collaboration to evaluate Everads' suprachoroidal delivery technology with a clinical-stage gene therapy company. Under the collaboration, the partner was given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties.
  • Global Pharmaceutical Company (unnamed)coreTechnology or Integration · 1 March 2020Option agreement with global pharma company to license Everads' suprachoroidal delivery system for retinal disease therapies. The agreement supports the potential of Everads' novel technology for delivery of posterior segment therapeutics to the suprachoroidal space. In August 2020, the company exercised rights for exclusive use of Everads' technology in specific retinal targets.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Everads Therapy competitors and assessment

Company assessment

Emerging players

  • Kriya Therapeutics: Kriya is an Everads partner developing gene therapies for prevalent ophthalmology diseases including geographic atrophy. While not a direct delivery device competitor, Kriya operates in the same ocular gene therapy value chain and represents both a customer and a strategic reference point for SCS-enabled therapeutics.
  • Adverum Biotechnologies: Adverum develops AAV-based gene therapies for retinal diseases including wet AMD and diabetic macular edema, utilizing intravitreal delivery. Both Everads and Adverum compete in the broader ocular gene therapy delivery ecosystem with overlapping indication focus.
  • 4D Molecular Therapeutics: 4DMT develops customized AAV vectors for retinal and other diseases with an active ocular gene therapy pipeline. Both companies serve the emerging gene therapy delivery market, with overlapping customer base of pharma partners developing retinal disease therapeutics.
  • Kodiak Sciences: Kodiak develops novel biologics and conjugates (ABC platform) for retinal vascular diseases including wet AMD and DME. Both companies pursue improved durability of treatment for retinal diseases through differentiated therapeutic and delivery approaches.

Broad incumbents

  • Santen Pharmaceutical: Santen is a global ophthalmology-focused pharmaceutical company with products for retinal diseases, glaucoma, and dry eye. As a large incumbent in ophthalmic therapeutics, Santen represents a potential licensing partner and competitor in the broader retinal disease treatment landscape.
  • Ocular Therapeutix: Ocular Therapeutix develops sustained-release ocular drug delivery platforms including DEXTENZA for post-surgical ocular inflammation and pain. Both companies develop drug delivery technologies for ocular indications, though Ocular Therapeutix focuses on anterior segment while Everads targets posterior segment.
  • Bausch + Lomb: Bausch + Lomb is a major ophthalmic pharmaceutical and device company with products across retinal diseases (e.g., Visudyne, enVista). Its broad portfolio in retinal therapeutics makes it a potential strategic acquirer or licensing partner for suprachoroidal delivery technology.

Direct peers

  • Clearside Biomedical: Clearside is the most direct competitor in suprachoroidal space delivery, with its commercially approved XIPERE SCS Microinjector for macular edema and active partnerships with large pharma. Both companies target the SCS delivery route for posterior segment therapeutics with injection-based devices.
  • REGENXBIO: REGENXBIO develops AAV gene therapies for retinal diseases (RGX-314) using suprachoroidal delivery, partnering with AbbVie. Both companies are pursuing SCS delivery as the enabling route for ocular gene therapy, addressing overlapping indications such as wet AMD and diabetic retinopathy.
  • EyePoint Pharmaceuticals: EyePoint develops sustained-release ocular drug delivery technologies including DURYSTA and bioerodible implants for retinal diseases. Both Everads and EyePoint are ocular drug delivery platform companies targeting improved efficacy and durability of retinal disease treatments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Everads Therapy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Everads Therapy leadership team

Management profile

Number of profiles

Profiles1 record

Everads Therapy funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Everads Therapy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Everads Therapy

What does Everads Therapy do?

Everads Therapy develops and licenses a proprietary suprachoroidal (SCS) drug and cell delivery platform — the Everads Suprachoroidal Injector — that uses a geometrically-optimized non-sharp tissue separator to enable tangential injection into the suprachoroidal space for targeted delivery of gene therapies, cell therapies, anti-VEGF antibodies, suspensions, and slow-release formulations to the posterior segment and macula for retinal disease treatment.

Is Everads Therapy a public or private company?

Everads Therapy is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Everads Therapy founded?

Everads Therapy was founded in 2017. It employs 1 to 10 people.

Where is Everads Therapy based?

Everads Therapy is headquartered in Tel Aviv, Israel, in the Middle East region.

How does Everads Therapy make money?

Two revenue lines are on record. Technology licensing is the primary driver. The others are collaborative development partnerships.

Who are Everads Therapy's main competitors?

Emerging players on record are Kriya Therapeutics, Adverum Biotechnologies, 4D Molecular Therapeutics and Kodiak Sciences. Broad incumbents are Santen Pharmaceutical, Ocular Therapeutix and Bausch + Lomb. Direct peers are Clearside Biomedical, REGENXBIO and EyePoint Pharmaceuticals.

Does Everads Therapy have an API?

No public API is recorded for Everads Therapy.

What industry is Everads Therapy in?

Everads Therapy's product category is Ophthalmic Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournEverads Announces Publication of First-in-Human Clinical Data for Its Suprachoroidal Injector in Ophthalmology Science and Three Presentations at ARVO 2026Everads Therapy announced publication of first-in-human clinical trial data for its suprachoroidal injector in Ophthalmology Science, demonstrating favorable safety, tolerability, and device performance in patients with diabetic macular edema using triamcinolone acetonide suspension. The trial showed procedural feasibility in an office-based setting with thermal imaging confirming rapid, posteriorly directed drug distribution to the posterior pole and macular region. The company also announced three presentations at the ARVO 2026 Annual Meeting in Denver, Colorado this week.PR NewswireEverads Announces Publication of First-in-Human Clinical Data for Its Suprachoroidal Injector in Ophthalmology Science and Three Presentations at ARVO 2026Everads Therapy announced publication of first-in-human clinical data for its suprachoroidal injector in Ophthalmology Science, demonstrating favorable safety, tolerability, and ease of use in patients with diabetic macular edema. The clinical trial showed that the device achieved rapid, posteriorly directed drug distribution as visualized by thermal imaging. The company also announced three presentations at the ARVO 2026 Annual Meeting in Denver, Colorado this week.PR NewswireEverads Announces Two Oral Presentations at ASRS 2025, Including Full Clinical Trial Results with Its Novel Suprachoroidal InjectorEverads Therapy announced full results from its first-in-human clinical trial and new preclinical data at the ASRS 2025 Annual Meeting, demonstrating the safety, feasibility, and tolerability of its novel suprachoroidal injector for treating diabetic macular edema and retinal detachment. The preclinical study showed the injector can reliably deliver viscoelastic into the suprachoroidal space to create consistent buckles, positioning it as a potential in-office, minimally invasive alternative to traditional retinal detachment surgery. The company, a clinical-stage spin-out from DALI Medical Devices based in Israel, is advancing its suprachoroidal delivery platform for both drug administration and in-office retinal detachment repair.PR NewswireEverads Announces Five Abstracts Accepted for Presentation at ARVO 2025, Including First-in-Human Results Using its Novel Suprachoroidal InjectorEverads Therapy announced that five abstracts, including first-in-human clinical data, have been accepted for presentation at the ARVO 2025 Annual Meeting in Salt Lake City, Utah. The company's suprachoroidal injector demonstrated safety, feasibility, and ease of use in an open-label trial evaluating suprachoroidal administration of triamcinolone acetonide for diabetic macular edema. The presentations will also showcase the platform's potential across gene therapy, small molecules, and suprachoroidal buckling for retinal detachment repair.PR NewswireEverads Enters License Agreement with Kriya for Development of Ocular Gene Therapy Candidates Using Everads' Suprachoroidal Delivery TechnologyEverads Therapy announced a license, collaboration and supply agreement with Kriya Therapeutics to advance Kriya's portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery technology. Under the terms, Kriya received field-based exclusivity for gene therapy targeting prespecified therapeutic targets including ophthalmic diseases involving the complement cascade, while Everads retains rights to other therapeutic targets and non-gene therapy applications. Everads received an undisclosed upfront payment and is entitled to development milestones and royalties on net sales, following a year-long collaboration that included successful evaluation in non-human primate models with results published in Translational Vision Science and Technology.PR NewswireGlobal Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal TargetsEverads Therapy, an Israeli life sciences company, announced that a global pharmaceutical company has exercised its rights for time-limited exclusivity to use Everads' suprachoroidal drug delivery technology for specific ocular targets, representing a milestone achievement in their collaboration. In exchange for this exclusivity, Everads will receive a milestone payment while retaining rights to license its technology to other parties for non-reserved targets. The technology, originally conceived at the Sheba Medical Center, aims to improve treatment delivery for retinal and macular diseases.GlobesEverads Therapy wins retina commercialization option dealEverads Therapy signed a commercialization option agreement for its suprachoroidal drug-injection device, with the partner company undisclosed. The deal includes an advance, milestone payments, and revenue sharing if the product integrates with the partner's drug. Everads will continue independent development for other indications.PR NewswireEverads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease TherapiesEverads Therapy, an early-stage life sciences company based in Tel Aviv, Israel, has signed its first commercial agreement — an option agreement with a large global pharmaceutical company to evaluate and potentially license Everads' suprachoroidal delivery system for retinal disease therapies. Under the terms of the deal, the pharma company receives an exclusive option to enter a license agreement in exchange for a pre-defined up-front fee, milestone payments, and ongoing royalties. The agreement represents a validation of Everads' technology, which aims to overcome limitations of current intravitreal and subretinal injection methods for treating retinal and macular diseases.